A phase II study of gemcitabine combined with vinorelbine as first-line chemotherapy for metastatic breast cancer

Hematology/ Oncology and Stem Cell Therapy

Volumn 3, Issue 1, 2010, Pages 1-6

  Shehata, Samir ^a   Saad, Ebtesam ^b   Goda, Yasser ^c   El Mesidi, Salah ^b   Koheil, Hanaa ^d   Elzawhri, Heba ^e   Kandeel, Alaa ^c   Abdelhamid, Thoraya ^e   Zaki, Mounir ^f   Meshref, Mohamed ^b,g  

^a ASSIUT UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c ALEXANDRIA UNIVERSITY   (Egypt)

^d MINISTRY OF HEALTH   (Canada)

^e NATIONAL CANCER INSTITUTE   (Egypt)

^f MINISTRY OF HEALTH   (Egypt)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; GEMCITABINE; NAVELBINE;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; INJECTION SITE REACTION; LEUKOPENIA; LIVER FAILURE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; SEPTIC SHOCK; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 77953677333     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1658-3876(10)50049-9     Document Type: Article

References (41)

1. Kamannger F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-2150.
2. Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339:974-984.
3. Valero V, Hotobagyi GN. Are anthracyclinetaxane regimens the new standard of care in the treatment of breast cancer? J CLIN Oncol. 2003;21:959-962.
4. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metasstatic breast cancer. Oncologist. 2004;9:617-632.
5. Longley DB, Jonston PG. Molecular mechannisms of drug resistance. J Pathol. 2005;205:275-292.
6. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T. Multicentre, phase II study evaluatiing capecitabine monotherapy in paclitaxel-reffractory metastatic breast cancer. J Clin Oncol. 1999;17:485-493.
7. Fumoleau P, Largillier R, Clippe C, Dièras V, Orffeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Curé H, Vuillemin E, Morère JF, Montestruc F, Mouri Z, Namer M. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxe-pretreated metastatiic breast cancer. Eur J Cancer. 2004;40:536-542.
8. Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, Hohneker J. Intravenous vinorelbine as first -line and second - line therapy in advanced breast cancer. J Clin Oncol. 1995 Nov;13(11):2722-30.
9. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 1993 Jul;11(7):1245-52.
10. Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Horner D, Demaille A. Vinorellbine (Navelbine) as salvage treatment for advanced breast cancer. Ann Oncol. 1994 May;5(5):423-6.
11. Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, Adamkiewicz BB, Long CA. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1997;15:1395-1400.
12. Kornek GV, Ulrich-Pur H, Penz M, Haider K, Kwasny W, Depisch D, Kovats E, Lang F, Schneewweiss B, Scheithauer W. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol. 2001 Feb 1;19(3):621-7.
13. Ray-Coquard I, Biron P, Bachelot T, Guastalla JP, Catimel G, Merrouche Y, Droz JP, Chauvin F, Blay JY. Vinorelbine and cisplatin (CIVI C regimen) for the treatment of metastatic breast carcinoma after failuure of anthracycline and/or paclitaxel-containing regimens. Cancer. 1998 Jan 1;82(1):134-40.
14. Harris J, Morrow M, Norton L. Malignant tummors of the breast: Management of metastatic disease. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer Principles and practice of oncoloogy. Philadelphia, PA, Lipincott-Raven Publisheers. 1997;1602-1616.
15. Valenza R, Leonardi V, Gebbia V, Agostara B. Gemcitabine and vinorelbine in pretreated advvanced breast cancer: A pilot study. Ann Oncol. 2000 Apr;11(4):495-6.
16. Taligabue P, Mariani G, Brambilla C. Dosefinding of gemcitabine (G) plus vinorelbine (V) in metastatic breast cancer (MB C). Proc Am Soc Clin Oncol. 1999;18:112a (abstr 423).
17. Fleming ID, Cooper JS, Henson DE, Hutter RV P, Kennedy BJ, Murphy GP, O'Sullivan B, Sobin LH, Yarbro JW. American Joint Committee on Cancer, editors. 1997. AJJC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wandders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwytther SG. 2000. New guidelines to evaluate the ressponse to treatment in solid tumors. J Natl Cancer Inst 92(3):205-216.
19. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
20. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1-10.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-81.
22. Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, Adamkiewicz BB, Long CA. Doseintensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1997;15:1395-1400.
23. Zelek L, Barthier S, Riofrio M, Fizazi K, Rixe O, Delord JP, Le Cesne A, Spielmann M. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metasstatic breast carcinoma. Cancer. 2001;92:2267-72.
24. Modi S, Seidman AD. Single-agent gemcitabinne in the treatment of advanced breast cancer. Clin Breast Cancer. 2004;(suppl 3):S101-06.
25. Albain KS. Combining nucleoside analogues and taxanes: rational and clinical data in New Horizons in Antimetabolite Therapy for Breast Cancer (oral communication). San Antonio Breast Cancer Satellite Symposium; San Antonio, TX, USA; Dec 16, 2006.
26. Mavroudis D, Ardavanis A, Boukovinas I. A multicenter randomized study comparing vinorelbbine plus gemcitabine versus capecitabine monottherapy as salvage treatment in patient with advvanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. J Clin Oncol. 2006;24(18S):A658.
27. Dinota A, Bilancia D, Romano R, Manzione L. Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advvanced breast cancer. Breast Cancer Res Treat. 2005;89(1):1-3.
28. Sanal SM, Gokmen E, Karabulut B, Sezgin C. Gemcitabine and vinorelbine combination in pattients with metastatic breast cancer. Breast J. 2002;8(3):171-176.
29. Moser R, Hausmaninger H, Mlineritsch B. Gemcitabine and vinorelbine as first or second line therapy in patients with advanced breast canccera prospective phase II trial. Proc Am Soc Clin Oncol. 2001;20:A1973.
30. Haider K, Kornek GV, Kwasny W, Weinländer G, Valencak J, Lang F, Püribauer F, Kovats E, Deppisch D, Scheithauer W. Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor. Breast Cancer Res Treat. 1999;55(3):203-211.
31. Schmid P, Heilmann V, Schulz CO, Dieing A, Lehenbauer-Dehm S, Jehn C, Sezer O, Posssinger K, Flath B. Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/ or taxanes pretreated metastatic breast canccer: a phase II study. J Cancer Res Clin Oncol. 2005;131(9):568-574.
32. Zavettieri M, Raffaele M, Azzarello D. Phase II study of vinorelbine and gemcitabine in metasstatic breast cancer patients, previously treateed with anthracyclines and /or taxanes. Proc Am Soc Clin Oncol. 2003;22:A256.
33. Lobo F, Virizuela JA, Dorta FJ, Florián J, Lomas M, Jiménez E, López P, Casado V, Léon A, Estévez LG, Dómine M; Spanish Group for Research in Breast Cancer. Gemcitabine/ vinorelbine in metastatic breast cancer pattients previously treated with anthracyclines: results of a phase II trial. Clin Breast Cancer. 2003;4(1):46-50.
34. Stathopoulos GP, Rigatos SK, Pergantas N, Tsavdarides D, Athanasiadis I, Malamos NA, Stathopoulos JG. Phase II trial of biweekly admministration of vinorelbine and gemcitabine in pretreated advanced breast cancer. J Clin Onccol. 2002;20(1):37-41.
35. Valenza R, Leonardi V, Gebbia V, Agostara B. Gemcitabine and vinorelbine in pretreateed breast cancer: a pilot study. Ann Oncol. 2000;11(4):495-496.
36. Nicolaides C, Dimopoulos MA, Samantas E, Bafaloukos D, Kalofonos C, Fountzilas G, Razi E, Kosmidis P, Pavlidis N. Gemcitabine and vinorelbbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2000;11(7):873-875.
37. Donadio M, Ardine M, Berruti A, Ritorto G, Fea E, Mistrangelo M, Coccorullo Z, Bergnolo P, Comandone A, Bertetto O. Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol. 2003;52(2):147-152.
38. Schreder MT, Waples J, Gualtieri R. Phase II study of gemcitabine and vinorelbine in metasstatic breast carcinoma. Proc Am Soc Clin Onccol. 2003;22:A300.
39. Rossi E, Perrone F, Labonia V, Landi G, Nuzzo F, Amabile G, Gridelli C, Di Maio M, D'Aiuto G, de Matteis A. Is gemcitabine plus vinorelbine active in second-line chemotherapy of metasstatic breast cancer? A single-center phase 2 study. Oncol. 2003;64(4):479-480.
40. Gennatas C, Michalaki V, Mouratidou D, Tsavvaris N, Andreadis C, Psychogios J, Poulakaki N. Gemcitabine in combination with vinorelbine for heavily pretreated advanced breast cancer. Anticancer Res. 2006;26(1B):549-552.
41. Martín M, Ruiz A, Muñoz M, Balil A, García-Mata J, Calvo L, Carrasco E, Mahillo E, Casado A, García-Saenz JA, Escudero MJ, Guillem V, Jara C, Ribelles N, Salas F, Soto C, Morales-Vasquez F, Rodríguez CA, Adrover E, Mel JR; Spanish Breast Cancer Research Group (GEIC - CAM) trial. Gemcitabine plus vinorelbine verssus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Ressearch Group (GEI CAM) trial. Lancet Oncol. 2007 Mar;8(3):219-25.